Mu­ta­bilis re­ceives CARB-X grant for 'night­mare bac­te­ri­a' treat­ment; Ab­Sci and Xyphos shake hands on dis­cov­ery deal

On a mis­sion to sub­due the ris­ing glob­al threat of an­tibi­ot­ic re­sis­tance, the CARB-X ini­tia­tive has inked yet an­oth­er grant — this one for a French phar­ma work­ing on a treat­ment for so-called “night­mare bac­te­ria.”

Ro­mainville-based Mu­ta­bilis is get­ting up to $6.4 mil­lion to de­vel­op its pre­clin­i­cal pro­gram for Car­bapen­em-re­sis­tant En­ter­obac­terales (CRE) bac­te­ria, dubbed EBL-1463. CRE got the no­to­ri­ous nick­name “night­mare bac­te­ria,” be­cause of its ten­den­cy to cause dead­ly in­fec­tions in health­care set­tings. And it can’t be treat­ed with ex­ist­ing an­tibi­otics, ac­cord­ing to CARB-X.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER